Literature DB >> 9885886

Beta-adrenergic receptor-dependent and -independent stimulation of adenylate cyclase is impaired during severe sepsis in humans.

G Bernardin1, A D Strosberg, A Bernard, M Mattei, S Marullo.   

Abstract

OBJECTIVES: a) To investigate the functional consequences of sepsis on the beta-adrenergic signal transduction in human circulating lymphocytes; b) to appreciate sepsis-associated catecholamine and cytokine release.
DESIGN: Experimental, comparative study.
SETTING: Research laboratory in a university hospital.
SUBJECTS: Healthy controls (n = 10); critically ill patients who were not septic (n = 7); septic patients with severe sepsis or septic shock (n = 11).
MEASUREMENTS AND MAIN RESULTS: Experiments were carried out using freshly isolated peripheral blood mononuclear cells (PBMC). We measured beta-adrenergic receptor (betaAR) number and affinity, and intracellular cAMP content at baseline and after the pharmacological stimulation of each component of the beta-adrenergic complex: betaAR with isoproterenol, Gs-protein with sodium fluoride (NaF), adenylate cyclase with forskolin. Catecholamine (adrenaline, noradrenaline) and cytokine (TNFalpha, IL-1alpha, IL-1beta, IL-6) serum levels were measured. In both septic and non-septic patients we observed a similar 40 % down-regulation of betaARs compared to controls, and a reduced basal and isoproterenol-stimulated cAMP accumulation (p < 0.05). The cAMP production elicited by NaF or forskolin was lower in septic patients than in the controls (p < 0.01). Forskolin-stimulated cAMP accumulation was significantly lower in septic patients than it was in non-septic ones (p < 0.001). Catecholamine serum concentrations were increased in the two patient groups without any significant difference. Elevated cytokine serum levels were detected in 45% of the septic patients (versus 14% of non-septic patients p < 0.05).
CONCLUSIONS: Patients presenting with severe sepsis or septic shock have extended postreceptor defects of the beta-adrenergic signal transduction. This finding suggests a heterologous desensitization of adenylate cyclase stimulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9885886     DOI: 10.1007/s001340050768

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  26 in total

1.  Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine : MODI (f)Y trial.

Authors:  Sebastian Nuding; Henning Ebelt; Robert S Hoke; Annette Krummenerl; Andreas Wienke; Ursula Müller-Werdan; Karl Werdan
Journal:  Clin Res Cardiol       Date:  2011-06-03       Impact factor: 5.460

Review 2.  Bacteraemic pneumococcal pneumonia: current therapeutic options.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 3.  Use of inotropes and vasopressor agents in critically ill patients.

Authors:  Mansoor N Bangash; Ming-Li Kong; Rupert M Pearse
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

4.  Frontline Science: D1 dopaminergic receptor signaling activates the AMPK-bioenergetic pathway in macrophages and alveolar epithelial cells and reduces endotoxin-induced ALI.

Authors:  Nathaniel B Bone; Zhongyu Liu; Jean-Francois Pittet; Jaroslaw W Zmijewski
Journal:  J Leukoc Biol       Date:  2016-10-12       Impact factor: 4.962

Review 5.  The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.

Authors:  O Friedrich; M B Reid; G Van den Berghe; I Vanhorebeek; G Hermans; M M Rich; L Larsson
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

6.  Prognostic tools for elderly patients with sepsis: in search of new predictive models.

Authors:  Fernando-Miguel Gamboa-Antiñolo
Journal:  Intern Emerg Med       Date:  2021-04-13       Impact factor: 3.397

7.  The calcineurin inhibitor cyclosporine A improves lipopolysaccharide-induced vascular dysfunction but does not rescue from cardiovascular collapse in endotoxemic mice.

Authors:  Mette Stæhr; Apameh Khatam-Lashgari; Paul M Vanhoutte; Pernille B L Hansen; Boye L Jensen
Journal:  Pflugers Arch       Date:  2013-05-21       Impact factor: 3.657

8.  Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.

Authors:  Jean-Francois Dhainaut; Massimo Antonelli; Patrick Wright; Arnaud Desachy; Jean Reignier; Sylvain Lavoue; Julien Charpentier; Mark Belger; Michael Cobas-Meyer; Cornelia Maier; Mariano A Mignini; Jonathan Janes
Journal:  Intensive Care Med       Date:  2009-03-05       Impact factor: 17.440

9.  Overexpression of Hsp20 prevents endotoxin-induced myocardial dysfunction and apoptosis via inhibition of NF-kappaB activation.

Authors:  Xiaohong Wang; Basilia Zingarelli; Michael O'Connor; Pengyuan Zhang; Adeola Adeyemo; Evangelia G Kranias; Yigang Wang; Guo-Chang Fan
Journal:  J Mol Cell Cardiol       Date:  2009-06-06       Impact factor: 5.000

10.  Septic cardiomyopathy - A not yet discovered cardiomyopathy?

Authors:  Ursula Muller-Werdan; Michael Buerke; Henning Ebelt; Konstantin M Heinroth; Anja Herklotz; Harald Loppnow; Martin Ruß; Frithjof Schlegel; Axel Schlitt; Hendrik B Schmidt; Gerold Söffker; Karl Werdan
Journal:  Exp Clin Cardiol       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.